News & Updates

Patients with atrial high-rate episodes (AHRE) do not seem to benefit from anticoagulation with edoxaban, which has fallen short of reducing the composite outcome of stroke, systemic embolism, or cardiovascular death, according to the results of the NOAH-AFNET* 6 trial.

The updated cardiovascular disease (CVD) prediction algorithm SCORE2 can be used to estimate the 10-year CVD risk in individuals without diabetes or CVD in the Asia Pacific/Middle East region, according to a study presented at ESC 2023.

Monotherapy with recaticimab can significantly lower low-density lipoprotein cholesterol (LDL-C) levels in patients with nonfamilial hypercholesterolemia (non-FH) and mixed hyperlipidaemia, according to data from the phase III REMAIN-1 study presented at ESC 2023.

For individuals with type 2 diabetes, leading a healthy lifestyle and scoring high on the American Heart Association (AHA)’s Life's Essential 8 (LE8) metric can lead to lower risks of developing macrovascular and microvascular diseases, as shown in a study.

Among middle-aged and older women with hyperglycaemia, those with low osteocalcin levels are at high risk of cardiovascular diseases, according to a study.

Treatment with pitavastatin is associated with a significantly lower risk of cardiovascular (CV) events in people living with human immunodeficiency virus (HIV) as shown in the final analysis of the double-blind, placebo-controlled REPRIEVE trial presented at IAS 2023.

Supplementation with vitamin D appears to have a favourable effect on blood pressure levels, as shown in a study.